LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Orchard Therapeutics plc (“Orchard”) as depositary bank for its American Depositary Receipt (“ADR”) programme. Orchard’s ADRs trade on the Nasdaq Global Market under the symbol “ORTX.” Each ADR represents one ordinary share of Orchard.”
“We are pleased to have been selected by Orchard as depositary bank for its Nasdaq listed ADR programme,” said Dirk Jones, Global Head of Issuer Services, at Citi. “We look forward to supporting the expansion of Orchard’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
About Citi
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi
About Orchard Therapeutics
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.
